Ask AI
Treat to Target in CD
Interactive Case Challenge 1: Treat-to-Target in Crohn’s Disease 

Released: March 17, 2025

Activity

Progress
1
Course Completed

Case History and Presentation


Ms Lewis returns after 6 months on mirikizumab. She reports complete symptom resolution with no abdominal pain, normal bowel habits, and improved energy levels. Updated labs show CRP 1 mg/L and fecal calprotectin 40 μg/g, and repeat imaging shows no signs of active inflammation; mucosal healing is confirmed.  

Which of the following measures is the most important to sustain remission?